Bladder Cancer Clinical Trials (April 2026): 473 Recruiting Interventional Studies
Last updated: April 18, 2026
Current Clinical Trial Landscape
Active research areas in 2026:
- Enfortumab vedotin (ADC) + pembrolizumab as new first-line standard — replacing cisplatin-based chemo
- FGFR-targeted therapy (erdafitinib) for FGFR-altered tumors
- Novel ADCs: sacituzumab govitecan, sacituzumab tirumotecan, BL-B01D1, SHR-A2102
- Intravesical therapies for non-muscle-invasive bladder cancer (BCG alternatives)
- Neoadjuvant immunotherapy before radical cystectomy
Standard of care: Non-muscle-invasive (NMIBC): TURBT + intravesical BCG. Muscle-invasive (MIBC): neoadjuvant cisplatin-based chemo + radical cystectomy. Metastatic: enfortumab vedotin + pembrolizumab (first-line), or cisplatin/carboplatin + gemcitabine + avelumab maintenance.
Recruiting Trials by Disease Stage
Non-Muscle-Invasive Bladder Cancer (NMIBC)
BCG is standard but many patients are BCG-unresponsive. New intravesical and systemic options are being tested:
- BCG alternatives / additions:
- NCT06510374 - Nadofaragene firadenovec (gene therapy) vs observation in intermediate-risk NMIBC (Phase 3)
- NCT06545955 - Nadofaragene firadenovec ± BCG in BCG-naïve high-risk NMIBC (Phase 3)
- NCT07480356 - TARA-002 vs investigator's choice in BCG-unresponsive NMIBC (Phase 3)
- NCT06746455 - BCG for therapeutic use (Phase 3)
- NCT07464145 - NDV-01 (sustained-release gemcitabine-docetaxel) for NMIBC (Phase 3)
- HER2-targeted for NMIBC:
- NCT07207824 - Disitamab vedotin + BCG in HER2-expressing BCG-naïve high-risk NMIBC (Phase 3)
Muscle-Invasive Bladder Cancer (MIBC)
Neoadjuvant and perioperative immunotherapy trials — testing whether IO before/after surgery improves outcomes:
- Neoadjuvant / perioperative:
- NCT07268339 - Radiotherapy with radiosensitisation for MIBC (Phase 3)
- NCT06879145 - SHR-A2102 (ADC) + tislelizumab in MIBC (Phase 3)
- NCT07067749 - MRI-guided treatment optimization for MIBC (Phase 3)
Locally Advanced or Metastatic Urothelial Carcinoma
Enfortumab vedotin + pembrolizumab is becoming standard first-line. New ADCs and combinations are being tested:
- Novel ADCs:
- NCT07526792 - SYS6002 vs chemotherapy in previously treated urothelial carcinoma (Phase 3)
- NCT06857175 - BL-B01D1 vs chemotherapy in recurrent/metastatic urothelial carcinoma (Phase 3)
- NCT06738251 - SHR-A2102 vs investigator's choice in advanced urothelial carcinoma (Phase 3)
- NCT06196736 - 9MW2821 vs chemotherapy in previously treated urothelial carcinoma (Phase 3)
- NCT07419295 - Sacituzumab tirumotecan (Sac-TMT) for urothelial carcinoma (Phase 3)
- IO combinations:
- NCT06524544 - Pembrolizumab + sacituzumab govitecan vs standard in metastatic UC (Phase 3)
Upper Tract Urothelial Carcinoma (UTUC)
A distinct subtype affecting the renal pelvis and ureter — fewer trials but growing interest:
-
- NCT04574960 - NAUTICAL: Neoadjuvant treatment for upper tract invasive cancer (Phase 3)
- NCT04865939 - Gemcitabine vs water irrigation in upper tract urothelial carcinoma (Phase 3)
Showing selected notable trials. View all 473 recruiting interventional trials on ClinicalTrials.gov.
Frequently Asked Questions
How do I find bladder cancer clinical trials I'm eligible for?
Enter your bladder cancer details into ClinTrialFinder — including FGFR mutation status, muscle-invasive vs non-muscle-invasive, and prior treatments. The AI matches you with trials based on your specific profile in minutes.
What bladder cancer trials are currently recruiting?
There are 473 recruiting interventional trials for bladder and urothelial cancer including ADCs (enfortumab vedotin), FGFR inhibitors (erdafitinib), checkpoint immunotherapy, intravesical therapies, and novel combinations.
Find Bladder Cancer Trials Matched to Your Situation
Use ClinTrialFinder's AI-powered matching to find trials based on your specific condition.
Find Matching Trials
